A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia

This study is ongoing, but not recruiting participants.

First Received: August 3, 2005 Last Updated: June 2, 2006 History of Changes

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00127179

Purpose

The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.

Condition	Intervention	Phase
Benign Prostatic Hyperplasia	Drug: MK0906, finasteride / Duration of Treatment: 48 weeks Drug: Comparator: placebo / Duration of Treatment: 48 weeks	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia

Resource links provided by NLM:

Drug Information available for: Finasteride

Further study details as provided by Merck:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	600
Study Start Date:	January 2004

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00127179

Locations

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

Study ID Numbers:	2005_042
Study First Received:	August 3, 2005
Last Updated:	June 2, 2006
ClinicalTrials.gov Identifier:	NCT00127179 History of Changes
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Study placed in the following topic categories:

Finasteride
Hyperplasia
Prostatic Diseases
Prostatic Hyperplasia
Genital Diseases, Male

Additional relevant MeSH terms:

Finasteride
Hyperplasia
Pathologic Processes
Molecular Mechanisms of Pharmacological Action
Prostatic Diseases

Prostatic Hyperplasia
Enzyme Inhibitors
Genital Diseases, Male
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 10, 2009